Key facts
- It has raised $20.2M; the latest was Grant ($2.8M) in Mar 2025.
- Notable investors include National Institute for Health and Care Research, Riveria Investment Group, University College London.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Yaqrit
- ·The full record, as it builds
Funding rounds
No funding rounds for Yaqrit are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yaqrit
Operator of a clinical-stage liver disease company intended to develop end-to-end applications to prevent, treat and reverse advanced liver disease. The company integrates technical expertise, clinical trial design and execution with a global collaborator network to accelerate the development of programs for severely ill patients, enabling medical researchers to deliver clinical and commercial success.
- Sector
- Healthcare
- HQ
- Aldridge, United Kingdom
- Founded
- 2014
- Employees
- 12
- Website
- yaqrit.com/
- Ownership
- Privately Held (backing)
Yaqrit doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yaqrit shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yaqrit in its N-PORT filings yet. We sweep new filings monthly.